FSH通过SATB1调控上皮性卵巢癌ES-2细胞的增殖和侵袭活性

目的：探讨特异AT序列结合蛋白1（special AT-rich sequence-bindingprotein,SATB1）在卵泡刺激素（Follicle stimulating hor-mone,FSH）诱导的上皮性卵巢癌ES-2细胞增殖和侵袭中的作用。方法：以Real-timePCR检测不同浓度FSH（0、10、20、40、80mlU／ml）处理后sATB1基因mRNA表达水平的变化。实验分4组：①siCon组,转染si-阴性对照（si-Negativecontrol）序列的实验组,对SATBl无干扰作用;②siSATB1组：转染特异性干扰下调SATB1的siSATB1序列;（3）FSH＋siCon组：以FSH处理的siCon组;（4）FSH＋siSATBl组：以FSH处理的sisATB1组。MTT法检测4组细胞的增殖情况,Westernblotting技术检测4组细胞细胞周期蛋白（CyclinDl）,基质金属蛋白酶2（MMP．2）的蛋白表达情况,Transwell侵袭实验检测4组细胞侵袭能力的变化。结果：1．FSH＋siCon组的细胞增殖能力明显高于siCon组的细胞增殖能力,FSH＋siCon组的CyclinD1蛋白相对表达量0．90＋0．08明显高于siCon组的0．37＋0．01（P均〈0．01）,提示FSH具有促进ES．2细胞增殖的作用。2．FSH＋siCon组的穿膜细胞数（30212）个明显高于siCon组（13919）个,FSH＋siCon组的MMP．2蛋白相对表达量0．40＋0．01明显高于siCon组的0．28＋0．02,提示FSH具有促进ES．2细胞侵袭能力的作用。3．随着FsH浓度的增高,SATBlmRNA的表达量逐渐增加,分别为1,1．66±0．04,1．79±0．21,2.31±0．03,以FsH浓度为80mlU／m1时最显著（P〈0．05）。4．FSH＋siSATBl组的细胞增殖能力明显低于FSH＋siCon组的细胞增殖能力,FSH＋siSATBl组的CyclinD1蛋白相对表达量0．22±0．02明显低于FSH＋siCon组的0．90±0．08（P均〈0．01）;FSH＋siSATB1组的穿膜细胞数（5216）个低于FSH＋siCon组的（30212）个,FSH＋siSATB1组的MMP-2蛋白相对表达量0．15±0．00明显低于FSH＋siCon组的0．40±0．01（P均〈0．01）,FSH促进ES-2细胞增殖和侵袭的能力由于SATB1基因表达的下降而被阻断。结论：SATBl是FSH作用的重要靶分子,介导FSH对上皮性卵巢癌ES-2细胞系增殖、侵袭活性的调控。     

OCT4 介导卵泡刺激素对永生化人卵巢上皮细胞株增殖、 凋亡和侵袭能力的影响

目的:探讨OCT4基因对卵泡刺激素作用下的永生化人卵巢上皮细胞株(Moody细胞)增殖、凋亡和侵袭能力影响。方法:将不同浓度的FSH(0、25、50、100mIU/ml)作用于Moody细胞48小时,应用Western-blot技术检测OCT4表达情况。采用慢病毒介导将重组质粒OCT4稳定转染至人卵巢上皮细胞株中,应用Western-blot法鉴定OCT4蛋白表达情况。FSH以50 mIU/ml作为工作浓度,实验对象分为4组:①siCon组,转染空载体的阴性对照组;②OCT4组:稳定转染OCT4基因的Moody细胞组;③FSH+siCon组:以FSH处理的siCon组;④FSH+OCT4组:以FSH处理的OCT4组。采用MTT比色法检测各组细胞的增殖情况,流式细胞仪检测各组细胞凋亡情况,Transwell侵袭实验检测各组细胞侵袭能力的变化。结果:(1)随着FSH浓度的增加,Moody细胞中OCT4蛋白表达逐渐增高,在FSH浓度为50 mIU/ml时达最高;(2)OCT4基因成功转染至Moody细胞中,经Western-blot检测该基因在细胞中进行蛋白高表达;(3)FSH+OCT4组细胞增殖活性明显增高,同时凋亡率降低,与另外三组相比差异具有统计学意义(P<0.05);(4)在FSH作用下,转染OCT4后明显增强了细胞的侵袭能力,与另外三组相比差异具有统计学意义(P<0.05)。结论:OCT4介导了FSH对人卵巢上皮细胞增殖、凋亡、侵袭活性的调控。     

circ_0000218通过靶向吸附miR-1182对宫颈癌HeLa细胞增殖、迁移和侵袭的影响

目的探讨环状RNA 0000218(circ_0000218)是否通过靶向吸附miR-1182从而影响宫颈癌HeLa细胞增殖、迁移和侵袭。方法采用实时荧光定量PCR(RT-qPCR)技术分析43例宫颈癌患者癌组织、癌旁组织中circ_0000218和miR-1182的表达水平。根据转染序列不同分为si-NC组、si-circ_0000218组、miR-NC组、miR-1182组、pcDNA组、pcDNAcirc_0000218组、si-circ_0000218+anti-miR-NC组、si-circ_0000218+anti-miR-1182组。运用细胞计数试剂盒(CCK-8)法、Transwell实验分析circ_0000218和miR-1182表达对HeLa细胞增殖、迁移和侵袭的影响。蛋白质印迹法检测Ki-67、基质金属蛋白酶2(MMP-2)和MMP9蛋白表达。双荧光素酶报告实验和RT-qPCR分析circ_0000218和miR-1182的靶向关系。癌旁组织与宫颈癌组织比较采用配对t检验,两组间比较采用独立样本t检验进行统计学分析。结果宫颈癌组织中circ_0000218表达量高于癌旁组织(4.17±0.32比1.00±0.05),而miR-1182表达量低于癌旁组织(0.33±0.03比1.00±0.05),差异具有统计学意义(P均<0.001)。与si-NC组比较,si-circ_0000218组HeLa细胞增殖活力(0.86±0.04比0.37±0.03)、迁移数量[(86.73±7.13)个比(38.52±3.19)个]和侵袭数量[(66.80±4.95)个比(26.58±2.55)个]以及Ki-67(0.57±0.05比0.18±0.02)、MMP-2(0.74±0.07比0.28±0.03)和MMP-9蛋白表达量(0.64±0.04比0.22±0.02)降低,差异有统计学意义(P均<0.001).与miR-NC组比较,miR-1182组HeLa细胞增殖活力(0.88±0.04比0.46±0.04)、迁移数量[(89.74±5.53)个比(46.63±3.79)个]和侵袭数量[(68.03±4.34)个比(34.63±3.37)个]以及Ki-67(0.59±0.04比0.24±0.02)、MMP-2(0.76±0.05比0.33±0.03)和MMP-9蛋白表达量(0.66±0.04比0.29±0.03)降低,差异有统计学意义(P均<0.001)。circ_0000218靶向负调控miR-1182表达。与si-circ_0000218+anti-miR-NC组比较,si-circ_0000218+anti-miR-1182组HeLa细胞增殖活力(0.35±0.03比0.76±0.04)、迁移数量[(35.58±3.11)个比(77.04±4.08)个]和侵袭数量[(25.44±2.29)个比(57.61±3.47)个]以及Ki-67(0.16±0.02比0.46±0.04)、MMP-2(0.26±0.02比0.65±0.04)和MMP-9蛋白表达量(0.20±0.02比0.57±0.04)升高,差异有统计学意义(P均<0.001)。结论circ_0000218通过靶向吸附miR-1182可促进宫颈癌HeLa细胞增殖、迁移和侵袭。     

Nupr1调控非小细胞肺癌细胞迁移、凋亡机制的研究

目的:探讨核蛋白1(Nupr1)调控非小细胞肺癌细胞迁移、凋亡机制的研究。方法:肿瘤抑制剂盐酸素(salinomycin)不同时间处理非小细胞肺癌细胞A549后采用Western Blot法检测非小细胞肺癌细胞A549中Cleaved Caspase-3、Nupr1的蛋白表达;Transwell小室检测Nupr1基因沉默后非小细胞肺癌细胞A549细胞体外迁移、侵袭能力的变化;Western Blot法检测Nupr1沉默后非小细胞肺癌细胞A549 MMP-2、TIMP-1的蛋白表达;流式细胞仪检测Nupr1沉默后非小细胞肺癌细胞A549的凋亡情况。结果:与未经肿瘤抑制剂salinomycin处理对照组相比较,salinomycin处理后的非小细胞肺癌细胞A549中Nupr1蛋白表达量下降,Cleaved Caspase-3蛋白表达量升高,并且随着作用时间呈依赖关系。Nupr1-siRNA转染组的迁移能力相比对照组未转染组下降(64.4±7.2)%,Nupr1-siRNA转染组的侵袭能力相比对照组下降(58.7±7.3)%。与未转染Nupr1-siRNA对照组相比较,转染后TIMP-1的表达明显上调,而MMP-2的表达则明显下调。流式细胞仪检测结果显示Nupr1沉默后非小细胞肺癌细胞A549出现大量凋亡。结论:Nupr1基因沉默后通过上调TIMP-1的表达,下调MMP-2的表达降低肺癌A549细胞的侵袭和迁移能力,进而促进非小细胞肺癌细胞凋亡。     

甘草提取物通过调控miR-212-5p/BCL2L2 基因抑制甲状腺肿瘤细胞的增殖、迁移和侵袭

目的探讨甘草提取物GL-1对甲状腺肿瘤细胞增殖、迁移和侵袭的影响及其分子机制。方法以10、20、30 μg/mL GL-1处理甲状腺肿瘤细胞CAL-62,或在CAL-62细胞中转染miR-212-5p mimics、anti-miR-212-5p、si-BCL2L2、pcDNA-BCL2L2。其中转染pcDNA-BCL2L2细胞并以30 μg/mL GL-1处理。噻唑蓝比色法 (MTT)检测CAL-62细胞增殖,Transwell小室法检测CAL-62细胞迁移和侵袭,实时定量PCR (qPCR)检测CAL-62细胞中miR-212-5p表达,Western blot检测相关蛋白Bcl-2样蛋白2 (BCL2L2)、细胞周期蛋白D1 (Cyclin D1)和基质金属蛋白酶-2 (MMP-2)表达。生物学信息预测miR-212-5p的下游靶基因,双荧光素酶基因报告实验进一步验证。数据采用单因素方差分析、Tukey’s事后检验和t检验。结果与对照组相比,10、20、30 μg/mL浓度GL-1降低CAL-62细胞24、48、72 h的细胞活性 (P < 0.05),并呈剂量、时间依赖性。与对照组相比,10、20、30 μg/mL浓度GL-1干预后,CAL-62细胞侵袭数[(143.56±14.22)个、(100.32±10.23)个、(68.23±6.49)个比(189.65±15.23)个]、迁移数[(198.56±14.35)个、(141.35±12.58)个、(89.56±8.95)个比 (295.36±17.56)个]和BCL2L2蛋白表达量 (0.76±0.08、0.51±0.06、0.24±0.02比1.00±0.12)均降低 (P 均< 0.05),而miR-212-5p水平 (1.61±0.11、1.99±0.13、2.28±0.15比1.00±0.07)升高(P < 0.05),并呈剂量依赖性。过表达miR-212-5p和沉默BCL2L2表达在24、48、72 h时CAL-62细胞活性、细胞迁移数、侵袭数和Cyclin D1、MMP-2蛋白表达量降低 (P < 0.05)。生物学信息预测和双荧光素酶基因报告实验证实BCL2L2是miR-212-5p的靶基因。过表达miR-212-5p抑制BCL2L2蛋白水平,沉默miR-212-5p促进BCL2L2蛋白表达 (P < 0.05)。过表达BCL2L2可逆转GL-1对CAL-62细胞增殖、迁移、侵袭及Cyclin D1、MMP-2蛋白表达的抑制作用。结论 GL-1通过miR-212-5p/BCL2L2抑制甲状腺肿瘤细胞的增殖、迁移和侵袭。     

二氢杨梅素对人胃癌MKN45细胞迁移和侵袭的影响及其机制*

目的:探讨二氢杨梅素(DHM )对人胃癌MKN45细胞迁移和侵袭的作用及其分子机制。方法:培养人低分化胃癌MKN45细胞,用不同浓度的DHM(0,10,20,30,40,50 μmol/L)分别处理细胞24及48 h,每组实验重复3次,采用CCK8实验检测癌细胞增殖活力;划痕实验检测细胞迁移能力;Transwell小室检测细胞侵袭能力;免疫印迹分析细胞迁移和侵袭相关蛋白表达情况。结果:不同浓度DHM干预可降低MKN45细胞活力。20,30及40 μmol/L的DHM处理48 h可明显抑制细胞的迁移能力(P＜0.01)和侵袭能力(P＜0.05及0.01)。20及30 μmol/L的DHM处理48 h可增加E-cadherin蛋白表达(P＜0.01)、降低Vimentin表达(P＜0.01),从而逆转EMT过程;10,20及30 μmol/L的DHM处理48 h可明显降低pJNK的活性表达水平(P＜0.05及0.01),及MMP-2蛋白表达(P＜ 0.01);JNK通路特异性抑制剂SP600125预处理可明显促进DHM对癌细胞侵袭能力的抑制作用(P＜0.01)及降低MMP-2表达(P＜0.01)。结论:DHM具有抑制人胃癌MKN45细胞的迁移及侵袭的作用,其机制可能与通过JNK通路下调MMP-2蛋白表达水平、逆转上皮间质转化有关。     

HepaCAM联合藏红花素抑制前列腺癌细胞PC3迁移活性的研究

为研究肝细胞黏附分子(hepatocyte cell adhesion molecule,hepa CAM)联合藏红花素(crocin)对前列腺癌(prostate cancer,PCa)细胞PC3上皮间质转化(epithelial-mesenchymal transition,EMT)及侵袭转移的影响,采用细胞免疫荧光观察迁移相关蛋白的表达情况;划痕实验检测细胞侵袭转移能力;Transwell实验检测细胞体外迁移能力;实时荧光定量PCR、Western blotting检测EMT相关分子及基质金属蛋白酶-2(matrix metalloproteinase 2,MMP-2)和MMP-9的表达变化。实验显示,hepaCAM过表达腺病毒与藏红花素均可有效抑制PC3细胞的侵袭转移(p0.01),两者联用比单独应用效果更加明显(p0.01)。Q-PCR显示,过表达hepaCAM联合藏红花素组与单独处理组相比,MMP-2、MMP-9及波形蛋白(vimentin,VIM)mRNA表达水平下调更显著(p0.01);E-钙粘蛋白(E-cadherin,E-CA)m RNA水平上调更加明显(p0.01)。Western blotting显示,与过表达hepa CAM组或藏红花素组相比,两者联用组MMP-2、MMP-9、VIM蛋白表达量明显降低(p0.01),同时E-CA蛋白水平上调更加明显(p0.01)。因此得出以下结论,hepaCAM过表达腺病毒联合藏红花素可显著抑制PC3细胞的侵袭转移,作用机制或与EMT和MMPs的表达有关。     

卵巢癌中HMGB1、BRCA1和p62蛋白的表达与其化疗敏感性的相关性

为了探讨卵巢癌中HMGB1、BRCA1和p62蛋白的表达与化疗敏感性的相关性,培养卵巢癌顺铂化疗耐药细胞ES-2和敏感细胞SKVO3,顺铂100 mg/m2环境培养5 d,分别采用Western blotting法和RT-PCR方法检测两种细胞中的HMGB1、BRCA1和p62蛋白表达情况,采用流式细胞术测算细胞凋亡率。敏感组细胞SKOV3和耐药组细胞ES-2中,BRCA1蛋白表达率分别为(38.08±22.56)%和(45.65±22.42)%,HMGB1蛋白表达率分别为(75.13±16.45)%和(83.08±24.22)%,p62蛋白表达率分别为(52.31±25.13)%和(37.26±21.09)%;顺铂处理后,敏感组SKOV3细胞中BRCA1蛋白表达量显著提高(p0.05),耐药组ES-2细胞中p62蛋白相对表达量高于敏感组SKOV3细胞(p0.01)。卵巢癌化疗后HMGB1下调与BRCA1、p62上调共存;卵巢癌中BRCA1蛋白的不同表达与化疗敏感性相关,其水平变化有可能作为一种新的肿瘤标志物,动态观察卵巢癌病情进展,为临床治疗提供客观指标。     

TRBP2基因过表达对肺腺癌A549细胞增殖、迁移及侵袭的影响及可能机制

该文探讨了TAR RNA结合蛋白2(TAR RNA binding protein 2,TRBP2)基因对肺腺癌A549细胞增殖、迁移及侵袭的影响及可能机制。构建TRBP2慢病毒过表达载体,以不同感染复数(MOI)感染A549细胞,根据绿色荧光强度选择最适MOI值。荧光定量PCR(FQ-PCR)检测TRBP2、MMP-2(matrix metalloproteinase-2)、PKR(double-stranded RNA-dependent protein kinase)m RNA的表达量。免疫蛋白印记(Western blot)法检测TRBP2、MMP-2、PKR、p-PKR的表达。采用MTT法、平板克隆实验检测TRBP2基因对A549细胞增殖的影响,Transwell迁移及侵袭实验检测细胞迁移和侵袭能力,黏附实验检测同种细胞和异种细胞间黏附情况。结果发现,成功构建了TRBP2基因过表达的A549细胞株,与空载体组和对照组比较,TRBP2基因过表达组细胞侵袭、迁移能力明显增强(P0.05),同种细胞间黏附力减弱(P0.05)而异种细胞间黏附力增强(P0.05),增殖速度加快(P0.05)及克隆形成率增加(P0.05)。此外,MMP-2、TRBP2蛋白及m RNA表达量明显升高(P0.05);p-PKR蛋白表达量降低(P0.05);PKR蛋白及m RNA表达量无差异。对照组与空载体组之间比较,以上各项指标均没有明显差异(P0.05)。该研究表明,过表达TRBP2基因可能通过促进MMP-2的表达同时抑制PKR磷酸化来促进肺腺癌A549细胞增殖、迁移及侵袭。     

抑制营养缺乏自噬因子1表达对肝癌LM3细胞增殖的影响

目的探讨以透明质酸-聚乙烯亚胺/透明质酸-聚乙二醇(HA-PEI/HA-PEG)作为基因载体传递NAF1-siRNA对人肝细胞LM3进行增殖能力抑制的效果。方法将纳米复合物HA-PEI/HA-PEG与NAF1-siRNA复合,转染LM3细胞建立HNS组,等量NAF1-siRNA转染建立NSI组,另设未转染对照对照组,等量HA-PEI/HA-PEG干预细胞建立HAH组。采用荧光实时定量PCR检测细胞NAF1 mRNA的表达水平,采用Western blotting法检测NAF1、cyclin D1蛋白表达。采用MTT实验和平板克隆形成实验检测细胞增殖抑制效果。4组比较采用单因素方差分析,两两比较采用t检验。结果以对照组NAF1 mRNA的相对表达量为100﹪进行检测。HNS组NAF1 mRNA的相对表达量为(2.12±0.17)﹪,与对照组相比,差异具有统计学意义(t=14.17,P=0.04)。HNS组LM3细胞的NAF1蛋白和Cyclin D1蛋白的相对表达量分别为0.07±0.01、0.06±0.00,而对应蛋白在对照组LM3细胞中的相对表达量分别为0.37±0.08、0.16±0.03,差异具有统计学意义(t=37.72,20.96,P=0.01,0.03)。HNS组细胞测得的细胞增殖抑制率为(73.20±0.43)﹪,与对照组的(0.49±0.02)﹪相比差异具有统计学意义(t=11.92,P=0.01)。HNS组LM3细胞的平板克隆形成率(8.35±0.33)﹪明显低于对照组的(23.61±0.10)﹪(t=17.75,P=0.00,0.02)。结论纳米复合物HA-PEI/HA-PEG可高效递送NAF1-si RNA,对肝癌LM3细胞进行转染,抑制NAF1表达,进而通过降低Cyclin D1表达水平抑制肝癌细胞LM3的增殖。     

Phylogenetic position of Indian termites (Isoptera: Termitidae) with their respective genera inferred from DNA sequence analysis of the mitochondrial cytochrome oxidase gene subunit I compared to subunit II

It has been shown that over-expression of Special AT-rich binding protein 1 (SATB1) in breast cancer predicts a poor prognosis. This study was aimed at investigating the effects of silencing SATB1 on mesenchymal derived human osteosarcoma U2OS cells and the underlying mechanisms. The expressions of SATB1 and the related genes in the cells were detected by qRT-PCR and/or Western Blotting. SATB1 silencing was achieved by stable transfection with the vectors expressing small hairpin RNA versus SATB1. Cell proliferation was detected in a microplate reader with Cell Counting Kit-8 and the cell cycle was analyzed by flow cytometry using a cell cycle detection kit. The study found that SATB1 was particularly over-expressed in human osteosarcoma U2OS. Silencing SATB1 inhibited the proliferation of U2OS. It was found that inhibition of cell proliferation resulted from cell cycle arrest due to down-regulated expression of CFGF and JunB. The over-expression of SATB1 is responsible for abnormal proliferation of mesenchymal derived human Osteosatcoma U2OS cells, indicating that silencing SATB1 expression in the cells might be developed as an efficient osteosarcoma therapy. CTGF and JunB were involved in SATB1-mediated proliferation of U2OS cells.     

Special AT-rich sequence-binding protein 2 and its related genes play key roles in the differentiation of MC3T3-E1 osteoblast like cells

Special AT-rich sequence-binding protein (SATB) plays a critical role in bone generation and osteoblast differentiation. In the present study, the differentially expressed genes by SATB2 overexpression were analyzed in MC3T3-E1 osteoblast-like cells using Alizarin red S staining, wound healing assay and Agilent's Human Oligo Microarray. Calcium mineralization and motility were significantly enhanced in SATB2-overexpressed cells compared with untreated control. In addition, using the GeneSpringGX 7.3 program to compare the identified genes expressed in SATB2-overexpresed cells with untreated control, we found several unique genes closely associated with osteoblast differentiation, including SOX2, MBP2, WNT11 and MEN1 (up-regulated genes), and ILK, FGF23, FGFR2, and SNAI1 (down-regulated genes). Consistent with microarray data, real-time RT-PCR confirmed the significant up- and down-regulation of these genes at mRNA level in SATB2-overexpressed MC3T3-E1 cells. Overall, our findings suggest that the molecular regulation of SATB2 can be an attractive approach to develop a novel therapeutic strategy for bone-related diseases.     

Decreased expression of SATB2: a novel independent prognostic marker of worse outcome in laryngeal carcinoma patients

Background

To investigate the expression and role of special AT-rich sequence-binding protein-2 (SATB2) in laryngeal squamous cell carcinoma (LSCC) tissue and cell line (HEp2), and to evaluate the clinical and prognostic significance of SATB2 protein in patients with LSCC.

Methods

The expression of SATB2 was examined in LSCC tissue and HEp2 cells by Western-blotting, Real-time PCR and immunohistochemical staining. Cell growth curve assay and colony formation assay were used to verify the effect of SATB2 on the proliferation and tumor progression ability of HEp2 cells. Tumor formation assay in nude mice was used to analyze the effect of SATB2 on the tumorigenicity of HEp2 cells.

Results

The status of SATB2 protein in carcinoma tissues is much lower than that in paracarcinoma tissues. The overall survival of the patients with high SATB2 expression was significantly higher than the low SATB2 expression group. Lower or negative SATB2 expression was significantly correlated with advanced clinical staging, histological grade and tumor recurrence. In vitro experiments demonstrated that over-expression of SATB2 in HEp2 cells inhibited cell proliferation and tumor progression ability, and down-regulation of SATB2 showed the opposite effects. Over-expression of SATB2 repressed the tumorigenicity of HEp2 cells by in vivo experiments. Moreover, multivariate analysis suggested that SATB2 expression might be an independent prognostic indicator for the survival of LSCC patients after curative surgery.

Conclusions

SATB2 might involve in the development and progression of LSCC as a tumor suppressor, and thereby may be a valuable prognostic marker for LSCC patients.     

Effects of serum type on growth and permeability properties of cultured endothelial cells

Serum is frequently added to defined basal media as a source of certain nutrients and macromolecular growth factors essential for cell growth. The many different sera commercially available may not be equally suitable for all cell types. The effects of four sera, fetal bovine serum (FBS), calf bovine serum (CS), equine serum (ES-1), and plasma-derived equine serum (ES-2), on growth and permeability properties of cultured porcine endothelial cells were determined. The rate of DNA synthesis, measured as [3H]thymidine incorporation, reached a peak at around 24 h, regardless of serum type, and was most marked with ES-1- or ES-2-treated cells. However, when estimated by total DNA, FBS, CS, or ES-1 treatment resulted in greater cell proliferation than ES-2. Based on protein synthetic rate and total cell protein, both FBS and CS appeared to be most growth supporting. At 72 h after cell plating, albumin passage across cultured endothelial monolayers was elevated in ES-1- and ES-2-treated cells compared with FBS- or CS-treated cells. "Leaky" cell monolayers were most marked with ES-1-treated cells. Cells grown in ES-2- and particularly in ES-1-enriched media were larger and more spindle-shaped compared with the typical cobblestone appearance of cells cultured in media enriched with either FBS or CS. These data suggest that CS, but not ES-1 or ES-2, is an excellent substitute for FBS to support desirable growth properties of macrovascular endothelial cells in culture.     

特异AT序列结合蛋白-1促进胰岛素样生长因子 结合蛋白-2在K562细胞中的表达

探讨过表达特异AT序列结合蛋白-1 ( special AT-rich sequence binding protein ,SATB1)核基质结合区（MAR）结合蛋白对胰岛素样生长因子结合蛋白-2（IGFBP2）基因表 达的影响,并对其影响机制进行初步探索．首先用脂质体将SATB1的真核表达载体pcDNA3.1-SATB1转染至K562细胞,通过6周G418的筛选获得阳性克隆,RT-PCR、实时PCR及Western 印迹验证过表达情况,对阳性克隆细胞中IGFBP2的表达用RT-PCR、实时PCR及Western 印迹方法进行检测;然后用RNAi的方法干扰阳性细胞中SATB1 的表达后,同样用上述3种方法再次检测IGFBP2的表达状况;用生物信息学方法对IGFBP2基因进行MAR序列与SATB1结合位点搜索分析,寻找SATB1影响IGFBP2基因表达的机制．结果显示,在稳定转染的情况下,实验组K562-SATB1细胞与转染空载体pcDNA3.1的K562-3.1细胞和未转染细胞K562相比,IGFBP2 mRNA水平上调了近7倍,而蛋白水平变化不明显．RNA干扰后,IGFBP2的表达在mRNA水平也相应下调,蛋白水平的变化同样不明显．通过生物信息学分析发现,IGFBP2第1个内含子中可能存在2. 5 kb MAR样序列,且MAR样序列上存在多个SATB1的潜在结合位点．综上所述,过表达SATB1可以使K562细胞中IGFBP2 mRNA表达水平提高,而且其调控机制可能与SATB1直接和IGFBP2基因中的MAR样序列结合有关．     

Molecular correlates and prognostic significance of SATB1 expression in colorectal cancer

ABSTRACT: BACKGROUND: Special AT-rich sequence-binding protein 1 (SATB1) is a global gene regulator that has been reported to confer malignant behavior and associate with poor prognosis in several cancer forms. SATB1 expression has been demonstrated to correlate with unfavourable tumour characteristics in rectal cancer, but its association with clinical outcome in colorectal cancer (CRC) remains unclear. In this study, we examined the prognostic impact of SATB1 expression in CRC, and its association with important molecular characteristics; i.e. beta-catenin overexpression, microsatellite instability (MSI) screening status, and SATB2 expression. METHODS: Immunohistochemical expression of SATB1 and beta-catenin was assessed in tissue microarrays with tumours from 529 incident CRC cases in the prospective population-based Malmo Diet and Cancer Study, previously analysed for SATB2 expression and MSI screening status. Spearman[ACUTE ACCENT]s Rho and Chi-Square tests were used to explore correlations between SATB1 expression, clinicopathological and investigative parameters. Kaplan Meier analysis and Cox proportional hazards modelling were used to explore the impact of SATB1 expression on cancer specific survival (CSS) and overall survival (OS). RESULTS: SATB1 was expressed in 222 (42%) CRC cases and negative, or sparsely expressed, in adjacent colorectal mucosa (n = 16). SATB1 expression was significantly associated with microsatellite stable tumours (p < 0.001), beta-catenin overexpression (p < 0.001) and SATB2 expression (p < 0.001). While not prognostic in the full cohort, SATB1 expression was significantly associated with poor prognosis in SATB2 negative tumours (HR = 2.63; 95% CI 1.46-4.71; pinteraction = 0.011 for CSS and HR = 2.31; 95% CI 1.32-4.04; pinteraction = 0.015 for OS), remaining significant in multivariable analysis. CONCLUSIONS: The results of this study demonstrate that SATB1 expression in CRC is significantly associated with beta-catenin overexpression, microsatellite stability and SATB2 expression. Furthermore, SATB1 expression is a factor of poor prognosis in SATB2 negative tumours. Altogether, these data indicate an important role for SATB1 in colorectal carcinogenesis and suggest prognostically antagonistic effects of SATB1 and SATB2. The mechanistic basis for these observations warrants further study.Virtual slidesThe virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/1922643082772076.